NCT00216138 - Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions

Head and Neck Cancer

Interventions

DRUG

Docetaxel

Docetaxel 60 mg/m2 for 60 minutes, day 1 of each cycle

DRUG

Capecitabine

Capecitabine 825 mg/m2 po bid, days 1-14

DRUG

Premedication

Dexamethasone and antiemetic premedication

Trial Locations (18)

19713

Helen F. Graham Cancer Center, Newark

46202

Indiana University Cancer Center, Indianapolis

Quality Cancer Center (MCGOP), Indianapolis

46515

Elkhart Clinic, Elkhart

46527

Center for Cancer Care at Goshen Health System, Goshen

46601

Northern Indiana Cancer Research Consortium, South Bend

46815

Fort Wayne Oncology & Hematology, Inc, Fort Wayne

47150

Center for Cancer Care, Inc., P.C., New Albany

47303

Medical Consultants, P.C., Muncie

47714

Oncology Hematology Associates of SW Indiana, Evansville

47802

Providence Medical Group, Terre Haute

47804

AP&S Clinic, Terre Haute

47904

Arnett Cancer Care, Lafayette

49201

Center for Hematology-Oncology of S Michigan, Jackson

60637

University of Chicago, Chicago

63110

Siteman Cancer Center, St Louis

68114

Methodist Cancer Center, Omaha

02115

Dana Farber Cancer Institute, Boston